A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Public ClinicalTrials.gov record NCT04513925. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-Label, Randomized Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Patients With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer Who Have Not Progressed After Concurrent Platinum-Based Chemoradiation
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the efficacy and safety of atezolizumab in combination with tiragolumab compared with durvalumab in participants with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC) who have received at least two cycles of concurrent platinum-based chemoradiotherapy (CRT) and have not had radiographic disease progression.
Study identification
- NCT ID
- NCT04513925
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 829 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 24, 2020 (Actual)
- Primary completion
- May 27, 2025 (Actual)
- Completion
- Jul 31, 2025 (Actual)
- Last update posted
- Jun 3, 2026
2020 – 2025
United States locations
- U.S. sites
- 25
- U.S. states
- 16
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford University | Palo Alto | California | 94305 | — |
| Banner MD Anderson Cancer Center | Greeley | Colorado | 80631 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901-8101 | — |
| Cancer Care Centers of Brevard | Palm Bay | Florida | 32901 | — |
| Woodlands Medical Specialists, P.A. | Pensacola | Florida | 32503 | — |
| Florida Cancer Specialist, North Region | St. Petersburg | Florida | 33705 | — |
| Northwest Georgia Oncology Centers PC - Marietta | Marietta | Georgia | 30060 | — |
| Illinois Cancer Care | Peoria | Illinois | 61615 | — |
| New England Cancer Specialists | Brunswick | Maine | 04011 | — |
| Southcoast Health System | Fairhaven | Massachusetts | 02719 | — |
| Minnesota Oncology Hematology | Minneapolis | Minnesota | 55404 | — |
| HCA Midwest Health | Kansas City | Missouri | 64132 | — |
| Cox Health Systems | Springfield | Missouri | 65807 | — |
| Optum Health Care | Las Vegas | Nevada | 89106 | — |
| Comprehensive Cancer Centers of Nevada | Las Vegas | Nevada | 89128 | — |
| Titan Health Partners LLC, d/b/a Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| New York Oncology Hematology,P.C.-Albany | Albany | New York | 12208 | — |
| Mount Sinai Medical Center | New York | New York | 10029 | — |
| Montefiore Medical Center | The Bronx | New York | 10461 | — |
| Prisma Health ? Upstate | Greenville | South Carolina | 29615 | — |
| Tennessee Oncology Chattanooga | Chattanooga | Tennessee | 37403 | — |
| Sarah Cannon Research Institute / Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 164 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04513925, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 3, 2026 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04513925 live on ClinicalTrials.gov.